Atrash Shebli, Bano Kulsum, Harrison Bradley, Abdallah Al-Ola
Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, North Carolina, USA
Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, North Carolina, USA.
J Investig Med. 2020 Jun;68(5):956-964. doi: 10.1136/jim-2020-001290. Epub 2020 Mar 21.
Chimeric antigen receptor (CAR)-T-cell therapy has sparked a wave of optimism in hematological malignancies, reflected by the successful results of early clinical trials involving patients with pre-B-cell acute lymphoblastic leukemia, B-cell lymphomas and multiple myeloma. CAR-T-cell therapy is considered to be a novel immunotherapy treatment that has the potential for curing certain hematological cancers. However, as use of CAR-T-cell therapy has grown, new challenges have surfaced. These challenges include the process of manufacturing the CAR-T cells, the mechanisms of resistance that underlie disease relapse, adverse effects and cost. This review describes the published results of clinical trials and expected developments to overcome CAR-T resistance.
嵌合抗原受体（CAR）-T细胞疗法在血液系统恶性肿瘤领域引发了一股乐观情绪，早期针对前B细胞急性淋巴细胞白血病、B细胞淋巴瘤和多发性骨髓瘤患者的临床试验取得成功结果，便反映了这一点。CAR-T细胞疗法被认为是一种新型免疫疗法，有治愈某些血液系统癌症的潜力。然而，随着CAR-T细胞疗法的应用日益广泛，新的挑战也浮出水面。这些挑战包括CAR-T细胞的制造过程、疾病复发背后的耐药机制、不良反应和成本。本综述描述了临床试验已发表的结果以及克服CAR-T耐药性的预期进展。
